The course of pregnancy and labour in a patient with the remission of Cushing's disease treated with ibandronic acid (Bonviva) for severe steroid-induced osteoporosis. A case report and literature review
https://doi.org/10.14341/probl201359532-35
Abstract
Therapy with bisphosphonates (BP) is recognized to be "the golden standard" for the treatment of osteoporosis of different etiology. However, the data on the use of BP by the women during pregnancy and lactation are scarce. This paper reports a case of gestation, labour, and lactation in a patient treated with ibandronic acid (Bonviva) for severe steroid-induced osteoporosis attributable to Cushing's disease. To our knowledge, the application of ibandronic acid during pregnancy has never been described in the literature before. The present study has demonstrated that therapy with ibandronic acid does not necessarily require the interruption of pregnancy or cessation of birth feeding. Nevertheless, the treatment of the women of reproductive age with BP can be prescribed only upon strict indications.
References
1. Дедов И.И., Рожинская Л.Я., Белая Ж.Е. Роль и место бисфосфонатов в профилактике и лечении остеопороза. 10-летний опыт применения алендроната. Остеопороз и остеопатии 2005; 1: 20-30.
2. Белая Ж.Е., Рожинская Л.Я., Мельниченко Г.А. Ибандронат (Бонвива) - новое направление в лечении бисфосфонатами. Лучшая приверженность к лечению - лучший результат. Остеопороз и остеопатии 2006; 3: 23-29.
3. Белая Ж.Е., Рожинская Л.Я. Бисфосфонаты в терапии постменопаузального остеопороза. Доктор Ру 2010; 58: 7: 29-38.
4. Lekamwasam S., Adachi J.D., Agnusdei D., Bilezikian J., Boonen S., Borgstrom F., Cooper C., Diez Perez A., Eastell R., Hofbauer L.C., Kanis J.A., Langdahl B.L., Lesnyak O., Lorene R., McCloskey E., Messina O.D., Napoli N., Obermayer-Pietsch B., Ralston S.H., Sambrook P.N., Silverman S., Sosa M., Stepan J., Suppan G., Wahl D.A., Compston J.E. Joint IOF-ECTS GIO Guidelines Working Group (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Intern 2012; 23: 2257-2276.
5. Patlas N., Colomb G., Yaffe P., Pinto T., Breuer E., Ornoy A. Transplacental effects of bisphosphonates on fetal skeletal issification and mineralization in rats. Teratology 1999; 60: 68-73.
6. Ioannis S.P., Chrysoula L.G., Aikaterini K., George L.P., Papaioannou G., Nikolaos A., Symeon T. The use of bisphosphonates in women prior to or during pregnancy and lactation. J Hormon 2011; 10: 280-291.
7. Levy S., Fayez I., Taguchi N., Han J.-Y., Aiello J., Matsui D., Moretti M., Koren G., Ito S. Pregnancy outcome following in utero exposure to bisphosphonates. Bone 2009; 44: 428-430.
8. Amy E., Kaplan F.N., Lishner M., Koren G. FRCPC Taking bisphosphonates during pregnancy. Can Fam Phys 2003; 49: 1281-1282.
9. Losada I., Sartori L., Di Gianantonio E., Zen M., Clementi M., Doria A. Pregnancy - and lactation-associated osteoporosis Davey at all. Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age? Autoimm Rev 2010; 9: 8: 547-552.
10. Vujasinovic-Stupar N., Pejnovic N., Markovic L., Zlatanovic M. Pregnancy-associated spinal osteoporosis treated with bisphosphonates: long-term follow-up of maternal and infants outcome. Reumatol Int 2012; 32: 3: 819-823.
11. Stathopoulos P. Ioannis, Liakou G. Chrysoula, Katsalira Aikaterini, Trovas George, Lyritis P. George, Papaioannou A. Nikolaos. Tournis Symeon The use of bisphosphonates in women prior to or during pregnancy and lactation. Hormones 2011; 10: 4: 280-291.
12. Body J.J., Pfister T., Bauss F. Preclinical perspectives on bisphosphonate renal safety. Oncologist 2005; 19: Suppl: 3-7.
13. Белая Ж.Е., Рожинская Л.Я. Бисфосфонаты: мифы и реальность. Эффективная фармакотерапия в эндокринологии 2010; 52-58.
14. Белая Ж.Е., Ильин А.В., Мельниченко Г.А., Рожинская Л.Я., Драгунова Н.В., Дзеранова Л.К., Огнева Н.А., Бутрова С.А., Трошина Е.А, Колесникова Г.С., Дедов И.И. Автоматизированный электрохемилюминисцентный метод определения кортизола в слюне для диагностики эндогенного гиперкортицизма среди пациентов с ожирением. Ожирение и метаболизм 2011; 27: 2: 56-63.
15. Дедов И.И., Белая Ж.Е., Ситкин И.И., Марова Е.И., Пржиялковская Е.Г., Ремизов О.В., Рожинская Л.Я. Значение метода селективного забора крови из нижних каменистых синусов в дифференциальной диагностике АКТГ-зависимого гиперкортицизма. Пробл эндокринол 2009; 55: 35-40.
16. Дедов И.И., Ситкин И.И., Белая Ж.Е., Марова Е.И., Пржиялковская Е.Г., Ремизов О.В., Рожинская Л.Я. Первый опыт использования селективного забора крови из нижних каменистых синусов в России (клиническое наблюдение). Пробл эндокринол 2009; 55: 11-16.
17. Belaya Z., Sitkin I., Rozhinskaya L., Dzeranova L., Marova E., Arapova S., Molitvoslovova N., Kolesnikova G., Melnichenko G. Usefulness of Prolactin IPS/P ratio and dominant ACTH/Prolactin ratio in bilateral inferior petrosal sinus sampling with desmopressin stimulation in patients with ACTH-dependent Cushing's syndrome. Austr J Clin Endocrinol Metabol 2012; 5: Special Issue: 3: 21.
Review
For citations:
Dragunova N.V., Belaia Zh.E., Kolesnikova G.S., Rozhinskaia L.I. The course of pregnancy and labour in a patient with the remission of Cushing's disease treated with ibandronic acid (Bonviva) for severe steroid-induced osteoporosis. A case report and literature review. Problems of Endocrinology. 2013;59(5):32-35. (In Russ.) https://doi.org/10.14341/probl201359532-35
Views:
1032
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
